Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9288MR)

This product GTTS-WQ9288MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9288MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3785MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ2202MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ12245MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ10112MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ15825MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ6322MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ2230MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ7328MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FPA-144
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW